Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 604

1.

Hypoglycemia and Elevated Troponin in Patients With Diabetes and Coronary Artery Disease.

Rezende PC, Everett BM, Brooks MM, Vlachos H, Orchard TJ, Frye RL, Bhatt DL, Hlatky MA.

J Am Coll Cardiol. 2018 Oct 9;72(15):1778-1786. doi: 10.1016/j.jacc.2018.07.067.

PMID:
30286920
2.
3.

Intravenous immunoglobulin for the treatment of autoimmune encephalopathy in children with autism.

Connery K, Tippett M, Delhey LM, Rose S, Slattery JC, Kahler SG, Hahn J, Kruger U, Cunningham MW, Shimasaki C, Frye RE.

Transl Psychiatry. 2018 Aug 10;8(1):148. doi: 10.1038/s41398-018-0214-7.

4.

Multivariate techniques enable a biochemical classification of children with autism spectrum disorder versus typically-developing peers: A comparison and validation study.

Howsmon DP, Vargason T, Rubin RA, Delhey L, Tippett M, Rose S, Bennuri SC, Slattery JC, Melnyk S, James SJ, Frye RE, Hahn J.

Bioeng Transl Med. 2018 Jun 19;3(2):156-165. doi: 10.1002/btm2.10095. eCollection 2018 May.

5.

A Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic Steatohepatitis.

Kawaguchi-Suzuki M, Cusi K, Bril F, Gong Y, Langaee T, Frye RF.

Front Pharmacol. 2018 Jul 17;9:752. doi: 10.3389/fphar.2018.00752. eCollection 2018.

6.

Clinical and Molecular Characteristics of Mitochondrial Dysfunction in Autism Spectrum Disorder.

Rose S, Niyazov DM, Rossignol DA, Goldenthal M, Kahler SG, Frye RE.

Mol Diagn Ther. 2018 Oct;22(5):571-593. doi: 10.1007/s40291-018-0352-x. Review.

7.

Impact of treatment strategies on outcomes in patients with stable coronary artery disease and type 2 diabetes mellitus according to presenting angina severity: A pooled analysis of three federally-funded randomized trials.

Mancini GBJ, Boden WE, Brooks MM, Vlachos H, Chaitman BR, Frye R, Bittner V, Hartigan PM, Dagenais GR.

Atherosclerosis. 2018 Oct;277:186-194. doi: 10.1016/j.atherosclerosis.2018.04.005. Epub 2018 Jun 1.

8.

Transport of a manganese/zinc ethylene-bis-dithiocarbamate fungicide may involve pre-synaptic dopaminergic transporters.

Montgomery K, Corona C, Frye R, Barnett R, Bailey A, Fitsanakis VA.

Neurotoxicol Teratol. 2018 Jul - Aug;68:66-71. doi: 10.1016/j.ntt.2018.05.004. Epub 2018 May 26.

PMID:
29807111
9.

Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitis.

Kalavalapalli S, Bril F, Koelmel JP, Abdo K, Guingab J, Andrews P, Li WY, Jose D, Yost RA, Frye RF, Garrett TJ, Cusi K, Sunny NE.

Am J Physiol Endocrinol Metab. 2018 Aug 1;315(2):E163-E173. doi: 10.1152/ajpendo.00023.2018. Epub 2018 Apr 10.

PMID:
29634314
10.

Metabolomic association between venous thromboembolism in critically ill trauma patients and kynurenine pathway of tryptophan metabolism.

Voils SA, Shahin MH, Garrett TJ, Frye RF.

Thromb Res. 2018 May;165:6-13. doi: 10.1016/j.thromres.2018.03.003. Epub 2018 Mar 8.

PMID:
29544199
11.

Comparison of Treatment for Metabolic Disorders Associated with Autism:Reanalysis of Three Clinical Trials.

Delhey LM, Tippett M, Rose S, Bennuri SC, Slattery JC, Melnyk S, James SJ, Frye RE.

Front Neurosci. 2018 Feb 12;12:19. doi: 10.3389/fnins.2018.00019. eCollection 2018.

12.

Butyrate enhances mitochondrial function during oxidative stress in cell lines from boys with autism.

Rose S, Bennuri SC, Davis JE, Wynne R, Slattery JC, Tippett M, Delhey L, Melnyk S, Kahler SG, MacFabe DF, Frye RE.

Transl Psychiatry. 2018 Feb 2;8(1):42. doi: 10.1038/s41398-017-0089-z.

13.

Modulation of Immunological Pathways in Autistic and Neurotypical Lymphoblastoid Cell Lines by the Enteric Microbiome Metabolite Propionic Acid.

Frye RE, Nankova B, Bhattacharyya S, Rose S, Bennuri SC, MacFabe DF.

Front Immunol. 2017 Dec 22;8:1670. doi: 10.3389/fimmu.2017.01670. eCollection 2017.

14.

Sphingolipid Metabolic Pathway Impacts Thiazide Diuretics Blood Pressure Response: Insights From Genomics, Metabolomics, and Lipidomics.

Shahin MH, Gong Y, Frye RF, Rotroff DM, Beitelshees AL, Baillie RA, Chapman AB, Gums JG, Turner ST, Boerwinkle E, Motsinger-Reif A, Fiehn O, Cooper-DeHoff RM, Han X, Kaddurah-Daouk R, Johnson JA.

J Am Heart Assoc. 2017 Dec 29;7(1). pii: e006656. doi: 10.1161/JAHA.117.006656.

15.

Relative Bioavailability of Silybin A and Silybin B From 2 Multiconstituent Dietary Supplement Formulations Containing Milk Thistle Extract: A Single-dose Study.

Li WY, Yu G, Hogan RM, Mohandas R, Frye RF, Gumpricht E, Markowitz JS.

Clin Ther. 2018 Jan;40(1):103-113.e1. doi: 10.1016/j.clinthera.2017.11.013. Epub 2017 Dec 19.

PMID:
29273470
16.

Response to Newman et al.

Parikh S, Goldstein A, Karaa A, Koenig MK, Anselm I, Brunel-Guitton C, Christodoulou J, Cohen BH, Dimmock D, Enns GM, Falk MJ, Feigenbaum A, Frye RE, Ganesh J, Griesemer D, Haas R, Horvath R, Korson M, Kruer MC, Mancuso M, McCormack S, Josee Raboisson M, Reimschisel T, Salvarinova R, Saneto RP, Scaglia F, Shoffner J, Stacpoole PW, Sue CM, Tarnopolsky M, Van Karnebeek C, Wolfe LA, Zolkipli Cunningham Z, Rahman S, Chinnery PF.

Genet Med. 2017 Dec;19(12). doi: 10.1038/gim.2017.164. Epub 2017 Oct 26. No abstract available.

PMID:
29215644
17.

High Rate of Recurrent De Novo Mutations in Developmental and Epileptic Encephalopathies.

Hamdan FF, Myers CT, Cossette P, Lemay P, Spiegelman D, Laporte AD, Nassif C, Diallo O, Monlong J, Cadieux-Dion M, Dobrzeniecka S, Meloche C, Retterer K, Cho MT, Rosenfeld JA, Bi W, Massicotte C, Miguet M, Brunga L, Regan BM, Mo K, Tam C, Schneider A, Hollingsworth G; Deciphering Developmental Disorders Study, FitzPatrick DR, Donaldson A, Canham N, Blair E, Kerr B, Fry AE, Thomas RH, Shelagh J, Hurst JA, Brittain H, Blyth M, Lebel RR, Gerkes EH, Davis-Keppen L, Stein Q, Chung WK, Dorison SJ, Benke PJ, Fassi E, Corsten-Janssen N, Kamsteeg EJ, Mau-Them FT, Bruel AL, Verloes A, Õunap K, Wojcik MH, Albert DVF, Venkateswaran S, Ware T, Jones D, Liu YC, Mohammad SS, Bizargity P, Bacino CA, Leuzzi V, Martinelli S, Dallapiccola B, Tartaglia M, Blumkin L, Wierenga KJ, Purcarin G, O'Byrne JJ, Stockler S, Lehman A, Keren B, Nougues MC, Mignot C, Auvin S, Nava C, Hiatt SM, Bebin M, Shao Y, Scaglia F, Lalani SR, Frye RE, Jarjour IT, Jacques S, Boucher RM, Riou E, Srour M, Carmant L, Lortie A, Major P, Diadori P, Dubeau F, D'Anjou G, Bourque G, Berkovic SF, Sadleir LG, Campeau PM, Kibar Z, Lafrenière RG, Girard SL, Mercimek-Mahmutoglu S, Boelman C, Rouleau GA, Scheffer IE, Mefford HC, Andrade DM, Rossignol E, Minassian BA, Michaud JL.

Am J Hum Genet. 2017 Nov 2;101(5):664-685. doi: 10.1016/j.ajhg.2017.09.008.

18.

Autistic Siblings with Novel Mutations in Two Different Genes: Insight for Genetic Workups of Autistic Siblings and Connection to Mitochondrial Dysfunction.

Burger BJ, Rose S, Bennuri SC, Gill PS, Tippett ML, Delhey L, Melnyk S, Frye RE.

Front Pediatr. 2017 Oct 12;5:219. doi: 10.3389/fped.2017.00219. eCollection 2017.

19.

Mitochondrial dysfunction in the gastrointestinal mucosa of children with autism: A blinded case-control study.

Rose S, Bennuri SC, Murray KF, Buie T, Winter H, Frye RE.

PLoS One. 2017 Oct 13;12(10):e0186377. doi: 10.1371/journal.pone.0186377. eCollection 2017.

20.

Bioenergetic variation is related to autism symptomatology.

Delhey L, Kilinc EN, Yin L, Slattery J, Tippett M, Wynne R, Rose S, Kahler S, Damle S, Legido A, Goldenthal MJ, Frye RE.

Metab Brain Dis. 2017 Dec;32(6):2021-2031. doi: 10.1007/s11011-017-0087-0. Epub 2017 Aug 29.

21.

Novel biomarkers of metabolic dysfunction is autism spectrum disorder: potential for biological diagnostic markers.

Khemakhem AM, Frye RE, El-Ansary A, Al-Ayadhi L, Bacha AB.

Metab Brain Dis. 2017 Dec;32(6):1983-1997. doi: 10.1007/s11011-017-0085-2. Epub 2017 Aug 22.

PMID:
28831647
22.

Folate metabolism abnormalities in autism: potential biomarkers.

Frye RE, Slattery JC, Quadros EV.

Biomark Med. 2017 Aug 3. doi: 10.2217/bmm-2017-0109. [Epub ahead of print]

23.
24.

Patient care standards for primary mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society.

Parikh S, Goldstein A, Karaa A, Koenig MK, Anselm I, Brunel-Guitton C, Christodoulou J, Cohen BH, Dimmock D, Enns GM, Falk MJ, Feigenbaum A, Frye RE, Ganesh J, Griesemer D, Haas R, Horvath R, Korson M, Kruer MC, Mancuso M, McCormack S, Raboisson MJ, Reimschisel T, Salvarinova R, Saneto RP, Scaglia F, Shoffner J, Stacpoole PW, Sue CM, Tarnopolsky M, Van Karnebeek C, Wolfe LA, Cunningham ZZ, Rahman S, Chinnery PF.

Genet Med. 2017 Dec;19(12). doi: 10.1038/gim.2017.107. Epub 2017 Jul 27. Review.

PMID:
28749475
25.

The Putative Role of Environmental Mercury in the Pathogenesis and Pathophysiology of Autism Spectrum Disorders and Subtypes.

Morris G, Puri BK, Frye RE, Maes M.

Mol Neurobiol. 2018 Jun;55(6):4834-4856. doi: 10.1007/s12035-017-0692-2. Epub 2017 Jul 22. Review.

PMID:
28733900
26.

Oxidative Stress Challenge Uncovers Trichloroacetaldehyde Hydrate-Induced Mitoplasticity in Autistic and Control Lymphoblastoid Cell Lines.

Frye RE, Rose S, Wynne R, Bennuri SC, Blossom S, Gilbert KM, Heilbrun L, Palmer RF.

Sci Rep. 2017 Jun 30;7(1):4478. doi: 10.1038/s41598-017-04821-3.

27.

Multiarterial grafts improve the rate of early major adverse cardiac and cerebrovascular events in patients undergoing coronary revascularization: analysis of 12 615 patients with multivessel disease.

Locker C, Schaff HV, Daly RC, Bell MR, Frye RL, Stulak JM, Said SM, Dearani JA, Joyce LD, Greason KL, Pochettino A, Li Z, Lennon RJ, Lerman A.

Eur J Cardiothorac Surg. 2017 Oct 1;52(4):746-752. doi: 10.1093/ejcts/ezx171.

PMID:
28595326
28.

Concentration-dependent response to pioglitazone in nonalcoholic steatohepatitis.

Kawaguchi-Suzuki M, Bril F, Kalavalapalli S, Cusi K, Frye RF.

Aliment Pharmacol Ther. 2017 Jul;46(1):56-61. doi: 10.1111/apt.14111. Epub 2017 May 3.

29.

The effect of milk thistle (Silybum marianum) and its main flavonolignans on CYP2C8 enzyme activity in human liver microsomes.

Albassam AA, Frye RF, Markowitz JS.

Chem Biol Interact. 2017 Jun 1;271:24-29. doi: 10.1016/j.cbi.2017.04.025. Epub 2017 Apr 27.

PMID:
28457856
30.

Presence of arachidonoyl-carnitine is associated with adverse cardiometabolic responses in hypertensive patients treated with atenolol.

Weng L, Gong Y, Culver J, Gardell SJ, Petucci C, Morse AM, Frye RF, Turner ST, Chapman A, Boerwinkle E, Gums J, Beitelshees AL, Borum PR, Johnson JA, Garrett TJ, McIntyre LM, Cooper-DeHoff RM.

Metabolomics. 2016 Oct;12(10). pii: 160. doi: 10.1007/s11306-016-1098-2. Epub 2016 Sep 15.

31.

Novel plasma biomarker of atenolol-induced hyperglycemia identified through a metabolomics-genomics integrative approach.

de Oliveira FA, Shahin MH, Gong Y, McDonough CW, Beitelshees AL, Gums JG, Chapman AB, Boerwinkle E, Turner ST, Frye RF, Fiehn O, Kaddurah-Daouk R, Johnson JA, Cooper-DeHoff RM.

Metabolomics. 2016 Aug;12(8). pii: 129. doi: 10.1007/s11306-016-1076-8. Epub 2016 Jul 13.

32.

The Effect of Mitochondrial Supplements on Mitochondrial Activity in Children with Autism Spectrum Disorder.

Delhey LM, Nur Kilinc E, Yin L, Slattery JC, Tippett ML, Rose S, Bennuri SC, Kahler SG, Damle S, Legido A, Goldenthal MJ, Frye RE.

J Clin Med. 2017 Feb 13;6(2). pii: E18. doi: 10.3390/jcm6020018.

33.

Thyroid dysfunction in children with autism spectrum disorder is associated with folate receptor α autoimmune disorder.

Frye RE, Wynne R, Rose S, Slattery J, Delhey L, Tippett M, Kahler SG, Bennuri SC, Melnyk S, Sequeira JM, Quadros EV.

J Neuroendocrinol. 2017 Mar;29(3). doi: 10.1111/jne.12461.

PMID:
28199771
34.

Cholelithiasis and Biliary Cirrhosis in a 28-Year-Old Man.

Francis FF, Frye R, Hashash JG.

Clin Gastroenterol Hepatol. 2017 May;15(5):A31-A32. doi: 10.1016/j.cgh.2017.01.013. Epub 2017 Jan 24. No abstract available.

PMID:
28130149
35.

SYNTAX Score and Long-Term Outcomes: The BARI-2D Trial.

Ikeno F, Brooks MM, Nakagawa K, Kim MK, Kaneda H, Mitsutake Y, Vlachos HA, Schwartz L, Frye RL, Kelsey SF, Waseda K, Hlatky MA; BARI-2D Study Group.

J Am Coll Cardiol. 2017 Jan 31;69(4):395-403. doi: 10.1016/j.jacc.2016.10.067.

36.

Modulation of the ultradian human nasal cycle by sleep stage and body position.

Frye RE, Rosin DF, Morrison AR, Leon-Sarmiento FE, Doty RL.

Arq Neuropsiquiatr. 2017 Jan;75(1):9-14. doi: 10.1590/0004-282X20160178.

37.

Mitochondrial and redox abnormalities in autism lymphoblastoid cells: a sibling control study.

Rose S, Bennuri SC, Wynne R, Melnyk S, James SJ, Frye RE.

FASEB J. 2017 Mar;31(3):904-909. doi: 10.1096/fj.201601004R. Epub 2016 Nov 18.

38.

Ixazomib cardiotoxicity: A possible class effect of proteasome inhibitors.

Jouni H, Aubry MC, Lacy MQ, Vincent Rajkumar S, Kumar SK, Frye RL, Herrmann J.

Am J Hematol. 2017 Feb;92(2):220-221. doi: 10.1002/ajh.24608. No abstract available.

39.

Pharmacogenomics competencies in pharmacy practice: A blueprint for change.

Roederer MW, Kuo GM, Kisor DF, Frye RF, Hoffman JM, Jenkins J, Weitzel KW.

J Am Pharm Assoc (2003). 2017 Jan - Feb;57(1):120-125. doi: 10.1016/j.japh.2016.08.014. Epub 2016 Nov 3.

40.

Maternal Obesity Programs Senescence Signaling and Glucose Metabolism in Osteo-Progenitors From Rat and Human.

Chen JR, Lazarenko OP, Blackburn ML, Rose S, Frye RE, Badger TM, Andres A, Shankar K.

Endocrinology. 2016 Nov;157(11):4172-4183. Epub 2016 Sep 21.

PMID:
27653035
41.

Modulation of mitochondrial function by the microbiome metabolite propionic acid in autism and control cell lines.

Frye RE, Rose S, Chacko J, Wynne R, Bennuri SC, Slattery JC, Tippett M, Delhey L, Melnyk S, Kahler SG, MacFabe DF.

Transl Psychiatry. 2016 Oct 25;6(10):e927. doi: 10.1038/tp.2016.189.

42.
43.

Folinic acid improves verbal communication in children with autism and language impairment: a randomized double-blind placebo-controlled trial.

Frye RE, Slattery J, Delhey L, Furgerson B, Strickland T, Tippett M, Sailey A, Wynne R, Rose S, Melnyk S, Jill James S, Sequeira JM, Quadros EV.

Mol Psychiatry. 2018 Feb;23(2):247-256. doi: 10.1038/mp.2016.168. Epub 2016 Oct 18.

44.

Complications Associated with Bar Fixation after Nuss Repair for Pectus Excavatum.

Shah M, Frye R, Marzinsky A, Phillips MR, Adamson W, McLean SE.

Am Surg. 2016 Sep;82(9):781-2. No abstract available.

45.

Early thrombin formation capacity in trauma patients and association with venous thromboembolism.

Voils SA, Lemon SJ, Jordan J, Riley P, Frye R.

Thromb Res. 2016 Nov;147:13-15. doi: 10.1016/j.thromres.2016.09.024. Epub 2016 Sep 20.

PMID:
27664391
46.

Enteric Ecosystem Disruption in Autism Spectrum Disorder: Can the Microbiota and Macrobiota be Restored?

Slattery J, MacFabe DF, Kahler SG, Frye RE.

Curr Pharm Des. 2016;22(40):6107-6121. Review.

PMID:
27592717
47.

Primary Mitochondrial Disease and Secondary Mitochondrial Dysfunction: Importance of Distinction for Diagnosis and Treatment.

Niyazov DM, Kahler SG, Frye RE.

Mol Syndromol. 2016 Jul;7(3):122-37. doi: 10.1159/000446586. Epub 2016 Jun 3. Review.

48.

Medical Treatment and Revascularization Options in Patients With Type 2 Diabetes and Coronary Disease.

Mancini GB, Farkouh ME, Brooks MM, Chaitman BR, Boden WE, Vlachos H, Hartigan PM, Siami FS, Sidhu MS, Bittner V, Frye R, Fuster V.

J Am Coll Cardiol. 2016 Sep 6;68(10):985-95. doi: 10.1016/j.jacc.2016.06.021.

49.

Concurrent Medical Conditions in Autism Spectrum Disorders.

Celia T, Freysteinson WW, Frye RE.

Pediatr Nurs. 2016 Sep-Oct;42(5):230-4. Review.

PMID:
29406641
50.

Sex Differences in Cardiac Troponin and the Risk of Death or Major Cardiovascular Events.

Everett BM, Brooks MM, Vlachos HE, Chaitman BR, Frye RL, Bhatt DL; BARI 2D Study Group.

J Am Coll Cardiol. 2016 Aug 30;68(9):978-80. doi: 10.1016/j.jacc.2016.06.013. No abstract available.

Supplemental Content

Support Center